Skip to main content
Premium Trial:

Request an Annual Quote

Ingenuity Extends Pathway Analysis Software Deal With Merck

NEW YORK (GenomeWeb News) — Ingenuity Systems today said it has extended a licensing agreement with Merck that allows the drug maker to continue using its Ingenuity Pathways Analysis Software.
 
Under the terms of the “multi-year” agreement, Merck will continue to use the IPA software for research in “multiple therapeutic areas,” Ingenuity said.
 
The original agreement was signed in 2004, but the company did not say when the extended licensing contract will expire.
 
Ingenuity said the software supports biomarker target identification and validation, predictive toxicology, and pharmacogenomics on “all high throughput analysis platforms.”
 
Financial terms of the agreement were not released.

Filed under

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.